October 7, 2026
U.S Cannabis Market – Q3 2026 Update
The third quarter of 2026 was another quarter of quiet progress. No single headline matched the drama of last December or last April, and that is the point. The industry spent the summer doing the unglamorous work of a maturing market: selling assets to operators who can run them, absorbing demand from a shrinking unregulated channel, and building the regulatory scaffolding for the next phase of growth.
Chicago Atlantic continued to originate attractive risk-reward in low-leverage loans to licensed operators across a variety of markets.
CONSOLIDATION: STRONGER HANDS
Consolidation was the story of the quarter, and it was orderly. Two of the industry’s larger operators, one public and one private, spent the year selling state-level licenses, cultivation, and retail to acquirers with the balance sheets to run them. The Cannabist Company sold its Virginia business for $130 million and used the proceeds to redeem secured notes at par, then entered a creditor-supported restructuring with agreements to sell operations in Ohio, Delaware, and six additional states. PharmaCann surrendered its Ohio facility, which was re-leased to Curaleaf within weeks, and sold its Colorado retail footprint to a well-capitalized regional operator. Landlords re-tenanted rather than wrote off. Lenders were repaid rather than impaired.
The result is fewer operators – and, we believe, better ones. Demand remained steady: August produced roughly $2.55 billion in legal sales nationally, near July’s record pace, and the first eight months of 2026 reached about $19.1 billion. We see volume now concentrating in the hands of operators who pay their rent and service their debt. Growth in this industry has always occurred at the edge of discomfort, and this quarter we saw that discomfort produce a stronger market.
HEMP: THE EXITS ARE ALREADY UNDERWAY
On September 2, a short-term funding bill moved the federal restrictions on intoxicating hemp products from November 12 to December 11, 2026, while leaving the November date in place for synthetic cannabinoids. The delay matters less than it appears. State enforcement is doing the work ahead of the federal calendar: Ohio’s Senate Bill 56 has channeled intoxicating products into licensed dispensaries since March, and Texas rules (effective March 31) removed the smokable products, which were a majority of many hemp retailers’ sales. Hemp businesses across the country are preparing to close most or all of their operations.
Many of our borrowers in enforcement states have begun to report measurable revenue lift as the hemp retail contracts and demand moves to licensed operators; with incremental sales landing on costs already paid. We expect the December date to bring further debate over delay, repeal, or regulation, but the migration of demand into licensed channels started before Congress acted and will likely continue regardless of how the calendar resolves.
STATE EXPANSION: MATURE MARKETS ALLOW SCALE
State-level progress this quarter came from established markets adjusting their rules to favor viable operators over fragmentation. Minnesota’s omnibus cannabis law took effect August 1, merging the medical and adult-use supply chains, creating a macro-business tier effective January 2027, and building a formal on-ramp for hemp operators to enter the licensed system. The state has issued well over 240 licenses and monthly sales have reached a record $22 million.
Massachusetts doubled the number of retail licenses a single operator may hold, from three to six, and paused new cultivation applications, opening retail consolidation while freezing supply.
Virginia confirmed a July 2027 launch for adult-use sales with license applications opening in February. Three states, three different tools, one direction.
RESCHEDULING: WATCHING CLOSELY
The Drug Enforcement Administration concluded its hearing on rescheduling the adult-use market on July 15, and post-hearing briefs were filed in August. The administrative law judge will issue a recommendation, after which the Administrator will make the final determination. Medical cannabis remains in Schedule III under April’s order, and operators have begun booking the resulting 280E relief in their financial statements. Adult-use operators continue to wait.
We are watching the process closely. We believe politicians do not score goals unless they get points for them, and the political value of completing rescheduling rises as the midterm elections approach. We therefore expect a more meaningful update in the coming months. Until then, fundamentals should continue to improve on the medical side while capital remains scarce on the adult-use side, and that combination continues to favor disciplined lenders.
OUR POSITIONING
Quiet quarters are when credit is built. The flywheel we described last quarter kept turning: regulatory reform pulls demand into licensed channels, that demand improves fundamentals, stronger fundamentals lift balance sheets, and healthier operators absorb the assets of weaker ones. Financing compliant operators still falls to a small group of specialized lenders. We have been among them since 2019, and few match our scale or tenure.
We seek to protect the downside through hard assets and disciplined structuring and hold upside through equity participation and relationships that compound. Nothing this quarter asks us to reposition. It asks us to keep doing what we do.
We appreciate your continued trust and look forward to updating you, as we expect these tailwinds to continue to translate into fundamentals.
Sources:
Cannabist asset sales and restructuring: The Cannabist Company, press releases on the sale of Virginia operations and closing of the transaction (Feb. 2026) and commencement of CCAA proceedings with asset sale agreements (Mar. 2026); SEDAR+ filings.
PharmaCann asset dispositions: Innovative Industrial Properties, Inc. (NYSE: IIPR), press releases and SEC filings on the Ohio property surrender and re-lease to Curaleaf (Apr. 2026); Grown Rogue International, announcement of the Illinois facility acquisition (Mar. 2026); acquirer press release on the Colorado retail transaction (2026).
National sales data: Industry sales tracking for July and August 2026 (monthly and year-to-date totals); state regulator reports.
Hemp deadline and state enforcement: H.R. 6500, Continuing Appropriations and Extensions Act, 2027 (signed Sept. 2, 2026); Foley Hoag, “A Temporary Reprieve for Hemp-THC Products” (Sept. 15, 2026); Ohio Senate Bill 56 (effective Mar. 20, 2026); Texas Department of State Health Services hemp rules (effective Mar. 31, 2026).
Hemp sellers closing: “American hemp sellers prepare for a looming ban on most of their products”, Wisconsin Public Radio (Sept 23, 2026), https://www.wpr.org/news/american-hemp-sellers-ban-products-thc-dispensary-cannabinoid-farm-bill
Minnesota omnibus law: Minnesota SF 4401, 2026 Omnibus Cannabis Bill (signed May 26, 2026; effective Aug. 1, 2026); Minnesota Office of Cannabis Management licensing and sales data; MPR News (May 28, 2026).
Minnesota license and sales data: “Minnesota: March Marijuana Sales Hit Record $22 Million, 2026 Total Reaches Around $60 Million, 148 Dispensaries Now Open”, The Marijuana Herald (Apr 6, 2026), https://themarijuanaherald.com/2026/04/minnesota-march-marijuana-sales-hit-record-22-million-2026-total-reaches-around-60-million-148-dispensaries-now-open/
Massachusetts reform: Massachusetts H.5350, An Act Modernizing the Commonwealth’s Cannabis Laws (signed Apr. 19, 2026); Cannabis Control Commission emergency regulations and cultivation application pause (Jun. 2026); MJBizDaily (Jun. 19, 2026).
Virginia adult-use market: Office of the Governor of Virginia, adult-use retail agreement (Jun. 16, 2026); enacted budget provisions setting Jul. 1, 2027 sales and Feb. 1, 2027 application dates.
DEA rescheduling hearing: DEA, Marijuana Rescheduling Regulatory Actions; hearing transcript and post-hearing briefing order of Chief ALJ (Jul. and Aug. 2026); Marijuana Moment coverage of hearing conclusion (Jul. 15, 2026).
280E relief for medical operators: Jushi Holdings Inc., Form 10-Q for the quarter ended Jun. 30, 2026; Curaleaf Holdings, Inc., quarterly report (Aug. 2026).Retail License Lottery Work?” (Mar. 13, 2026); Rhode Island Cannabis Control Commission, adult-use retail license materials